Kala Bio (KALA) Liabilities and Shareholders Equity (2016 - 2026)

Kala Bio has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $12.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 74.47% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.9 million (down 62.23% YoY) and the FY2025 annual result came in at $9.5 million, down 82.9% from the prior year.
• Liabilities and Shareholders Equity rose to $12.3 million in Q1 2026 per KALA's latest filing, from $9.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $111.6 million in Q1 2022 and troughed at $9.5 million in Q4 2025.
• A 5-year average of $57.7 million and a median of $55.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity retreated 0.83% in 2024, then slumped 82.9% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $86.8 million in 2022, then plunged by 35.56% to $55.9 million in 2023, then declined by 0.83% to $55.5 million in 2024, then plunged by 82.9% to $9.5 million in 2025, then increased by 29.8% to $12.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $12.3 million, $9.5 million, and $25.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.